Peer Review reports
From: Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells
| Original Submission | ||
|---|---|---|
| 25 Sep 2019 | Submitted | Original manuscript |
| 23 Oct 2019 | Reviewed | Reviewer Report - Karim Hosni |
| 15 Nov 2019 | Reviewed | Reviewer Report - Serawit Deyno |
| 10 Dec 2019 | Author responded | Author comments - Mitsuki Tabata |
| 25 Dec 2019 | Reviewed | Reviewer Report - Serawit Deyno |
| 13 Jan 2020 | Reviewed | Reviewer Report - Karim Hosni |
| 31 Jan 2020 | Author responded | Author comments - Mitsuki Tabata |
| Resubmission - Version 2 | ||
| 10 Dec 2019 | Submitted | Manuscript version 2 |
| 21 Feb 2020 | Author responded | Author comments - Mitsuki Tabata |
| Resubmission - Version 3 | ||
| 21 Feb 2020 | Submitted | Manuscript version 3 |
| 29 Feb 2020 | Author responded | Author comments - Mitsuki Tabata |
| Resubmission - Version 4 | ||
| 29 Feb 2020 | Submitted | Manuscript version 4 |
| Publishing | ||
| 4 Mar 2020 | Editorially accepted | |
| 14 Mar 2020 | Article published | 10.1186/s12906-020-2879-8 |
You can find further information about peer review here.